Sharma Om Prakash, Shah Mahek V, Parikh Dhaivat C, Mehta Tejal A
Nirma University, Institute of Pharmacy, Department of Pharmaceutics and Pharmaceutical Technology , S. G. Highway, Ahmedabad-382 481, Ahmedabad, Gujarat , India.
Expert Opin Drug Deliv. 2015 Apr;12(4):513-24. doi: 10.1517/17425247.2014.944861. Epub 2014 Nov 27.
The objective of the study was to develop gastroretentive dosage form (GRDF) for allopurinol (ALP) using combined approaches of mucoadhesion and floating systems. GRDF was systematically optimized using 3(2)-full factorial design.
Concentrations of sodium carboxymethyl cellulose (X1) and concentration of polyoxyethylene oxide WSR 303 (X2) were selected as independent variables, whereas gastroretentive parameters like total floating time (TFT) (Y1), mucoadhesive force (MF) (Y2), time required for 10% drug release (Y3) and time required for 80% drug release (Y4) were selected as dependent variables in development of robust GRDF of ALP. GRDF was evaluated for gastroretentive parameters such as floating lag time (FLT) and TFT, MF using texture analyzer and ex vivo residence time using modified disintegration test apparatus. Roentgenography study of optimized formulation was conducted to evaluate in vivo gastro retentive behavior using albino rabbits.
Developed tablets showed immediate in situ gas generation and exhibited FLT of 1.68 s after placing into simulated gastric fluid, which lead to buoyancy as well as controlled drug release for 24 h with zero-order drug release kinetics. The optimized formulation was selected based on in vitro drug release characteristics. In vivo retention of optimized formulation was corroborated using roentgenography studies.
The study concluded that the combination of mucoadhesive and floating approaches for GRDF aids to achieve desired gastroretentive performance and drug release properties for ALP. The formulation scientists may adopt these formulation strategies for drugs suitable for the development of GRDF.
本研究的目的是采用粘膜粘附和漂浮系统相结合的方法,开发用于别嘌醇(ALP)的胃滞留剂型(GRDF)。使用3(2)-全因子设计对GRDF进行系统优化。
选择羧甲基纤维素钠浓度(X1)和聚环氧乙烷WSR 303浓度(X2)作为自变量,而在开发稳健的ALP-GRDF时,选择胃滞留参数如总漂浮时间(TFT)(Y1)、粘膜粘附力(MF)(Y2)、10%药物释放所需时间(Y3)和80%药物释放所需时间(Y4)作为因变量。使用质构分析仪评估GRDF的胃滞留参数,如漂浮滞后时间(FLT)和TFT、MF,使用改良的崩解试验装置评估离体滞留时间。使用白化兔对优化制剂进行X线摄影研究,以评估体内胃滞留行为。
所制备的片剂显示出即时原位产气,放入模拟胃液后FLT为1.68 s,这导致了浮力以及24小时的控释,药物释放动力学为零级。根据体外药物释放特性选择优化后的制剂。通过X线摄影研究证实了优化制剂的体内滞留情况。
该研究得出结论,GRDF的粘膜粘附和漂浮方法相结合有助于实现ALP所需的胃滞留性能和药物释放特性。制剂科学家可将这些制剂策略应用于适合开发GRDF的药物。